PE20071037A1 - SALES Y FORMULACIONES DE 1-[5-(4-AMINO-7-ISOPROPIL-7H-PIRROLO[2,3-d]PIRIMIDIN-5-CARBONIL)-2-METOXI-FENIL]-3-(2,4-DICLORO-FENIL)-UREA - Google Patents
SALES Y FORMULACIONES DE 1-[5-(4-AMINO-7-ISOPROPIL-7H-PIRROLO[2,3-d]PIRIMIDIN-5-CARBONIL)-2-METOXI-FENIL]-3-(2,4-DICLORO-FENIL)-UREAInfo
- Publication number
- PE20071037A1 PE20071037A1 PE2006001565A PE2006001565A PE20071037A1 PE 20071037 A1 PE20071037 A1 PE 20071037A1 PE 2006001565 A PE2006001565 A PE 2006001565A PE 2006001565 A PE2006001565 A PE 2006001565A PE 20071037 A1 PE20071037 A1 PE 20071037A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- urea
- metoxy
- pyrrolo
- pyrimidin
- Prior art date
Links
- -1 4-AMINO-7-ISOPROPYL-7H-PYRROLO [2,3-d] PYRIMIDIN-5-CARBONYL Chemical class 0.000 title abstract 3
- 239000004202 carbamide Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 229920000609 methyl cellulose Polymers 0.000 abstract 2
- 239000001923 methylcellulose Substances 0.000 abstract 2
- 235000010981 methylcellulose Nutrition 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 239000007962 solid dispersion Substances 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA DISPERSION SOLIDA AMORFA DE 1-[5-(4-AMINO-7-ISOPROPIL-7H-PIRROLO[2,3-d]PIRIMIDIN-5-CARBONIL)-2-METOXI-FENIL]-3-(2,4-DICLORO-FENIL)-UREA Y UN POLIMERO PARA AUMENTAR LA CONCENTRACION TAL COMO ACETATO SUCCINATO DE HIDROXIPROPIL METILCELULOSA, EN DONDE DICHO COMPUESTO DE UREA COMPRENDE ENTRE 10% Y 40% EN PESO DE LA DISPERSION SOLIDA AMORFA. DICHA DISPERSION SOLIDA AMORFA ESTA MEZCLADA CON MAS POLIMEROS PARA AUMENTAR LA CONCENTRACION TALES COMO ACETATO DE HIDROXIPROPIL METIL CELULOSA, HIDROXIPROPIL METIL CELULOSA, HIDROXIPROPIL CELULOSA, METIL CELULOSA, HIDROXIETIL METIL CELULOSA, ENTRE OTROS. DICHA COMPOSICION FARMACEUTICA ES UTIL PARA EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74907005P | 2005-12-09 | 2005-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20071037A1 true PE20071037A1 (es) | 2007-11-19 |
Family
ID=38123252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006001565A PE20071037A1 (es) | 2005-12-09 | 2006-12-06 | SALES Y FORMULACIONES DE 1-[5-(4-AMINO-7-ISOPROPIL-7H-PIRROLO[2,3-d]PIRIMIDIN-5-CARBONIL)-2-METOXI-FENIL]-3-(2,4-DICLORO-FENIL)-UREA |
Country Status (8)
Country | Link |
---|---|
AR (1) | AR058293A1 (es) |
DO (1) | DOP2006000271A (es) |
GT (1) | GT200600496A (es) |
NL (1) | NL2000337A1 (es) |
PE (1) | PE20071037A1 (es) |
TW (1) | TW200733965A (es) |
UY (1) | UY29991A1 (es) |
WO (1) | WO2007066189A2 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090143423A1 (en) * | 2007-10-19 | 2009-06-04 | Abbott Gmbh & Co. Kg | Solid dispersion product containing n-aryl urea-based compound |
AU2008313622A1 (en) * | 2007-10-19 | 2009-04-23 | Abbott Gmbh & Co. Kg | Solid dispersion product of N-aryl urea-based drugs |
WO2010045542A2 (en) * | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
KR20120124428A (ko) | 2009-12-30 | 2012-11-13 | 아르퀼 인코포레이티드 | 치환된 피롤로-아미노피리미딘 화합물 |
CN103037843A (zh) * | 2010-06-23 | 2013-04-10 | 麦它波莱克斯股份有限公司 | 5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物 |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
EP2751112B1 (en) | 2011-09-02 | 2019-10-09 | The Regents of The University of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
US20140004192A1 (en) * | 2012-04-13 | 2014-01-02 | Ziopharm Oncology, Inc. | Pharmaceutical formulations of indibulin and uses thereof |
US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
MX2015003874A (es) | 2012-09-26 | 2015-12-16 | Univ California | Modulacion de ire1. |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
CN107722012B (zh) * | 2016-08-11 | 2020-05-29 | 斯福瑞(南通)制药有限公司 | 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
KR20210018264A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
PE20221085A1 (es) | 2019-10-14 | 2022-07-05 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含fgfr抑制劑及nectin-4靶向劑之組合療法 |
JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Fgfr阻害剤としての三環式ヘテロ環 |
JP2025015449A (ja) * | 2023-07-18 | 2025-01-30 | 信越化学工業株式会社 | 固体分散体用組成物、固体分散体及び固体分散体の製造方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE364374T1 (de) * | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
UA80171C2 (en) * | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
-
2006
- 2006-11-24 WO PCT/IB2006/003416 patent/WO2007066189A2/en active Application Filing
- 2006-11-27 NL NL2000337A patent/NL2000337A1/nl active Search and Examination
- 2006-12-05 DO DO2006000271A patent/DOP2006000271A/es unknown
- 2006-12-06 UY UY29991A patent/UY29991A1/es not_active Application Discontinuation
- 2006-12-06 PE PE2006001565A patent/PE20071037A1/es not_active Application Discontinuation
- 2006-12-07 AR ARP060105422A patent/AR058293A1/es unknown
- 2006-12-07 GT GT200600496A patent/GT200600496A/es unknown
- 2006-12-08 TW TW095145947A patent/TW200733965A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
GT200600496A (es) | 2007-07-17 |
UY29991A1 (es) | 2007-07-31 |
TW200733965A (en) | 2007-09-16 |
WO2007066189A3 (en) | 2008-08-14 |
DOP2006000271A (es) | 2007-08-15 |
WO2007066189A2 (en) | 2007-06-14 |
AR058293A1 (es) | 2008-01-30 |
NL2000337A1 (nl) | 2007-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20071037A1 (es) | SALES Y FORMULACIONES DE 1-[5-(4-AMINO-7-ISOPROPIL-7H-PIRROLO[2,3-d]PIRIMIDIN-5-CARBONIL)-2-METOXI-FENIL]-3-(2,4-DICLORO-FENIL)-UREA | |
MA29851B1 (fr) | Composes et compositions contenant de la diarylamine et utilisation en tant que modulateurs de recepteurs de c-kit | |
BRPI0513841A (pt) | composto, composição farmacêutica, e uso do composto | |
CO6511272A2 (es) | Compustos de pirazol como antahonistas de crth2 | |
BRPI0514738A (pt) | derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos | |
NI200700064A (es) | Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos. | |
AR054581A1 (es) | Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion | |
CY1115058T1 (el) | Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης | |
UY31124A1 (es) | Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842 | |
CL2009000662A1 (es) | Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios. | |
CR11441A (es) | Producto de dispersion solida que contiene un compuesto a base de n-aril urea | |
CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
UY31219A1 (es) | N-[3-(2,6-diclorofenil)-5-alquilo-1,2-oxazol-4-il carbamatos sustituidos y 1-[3-(2,6-diclorofenil)-5-metil-1,2-oxazol-4-il]ureas sustituidas asi como isomeros, sales farmacéuticas y usos de dichos compuestos | |
CL2012001366A1 (es) | Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras. | |
AR055319A1 (es) | Derivados de isoquinoleina, composiciones farmaceuticas y usos | |
UY31079A1 (es) | Derivados de fenilaminobenceno sustituidos de utilidad para el tratamiento de trastornos y enfermedades hiperproliferativos asociados con actividad quinasa extracelular mediada por mitógenos | |
AR060536A1 (es) | Agonista del receptor de glucocorticoides y composiciones farmaceuticas | |
ATE425961T1 (de) | Salze substituierter allophansaureester und deren verwendung in arzneimitteln | |
ECSP088829A (es) | Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1) | |
WO2008074833A3 (en) | Compounds | |
CL2009001267A1 (es) | Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis. | |
ATE473752T1 (de) | Verwendung von verbindungen zur induktion der synthese von sirt-proteinen bei der oder für die herstellung eines kosmetikums oder einer pharmazeutischen zusammensetzung | |
EA201000926A1 (ru) | Пиперазины в качестве агентов против ожирения | |
UY29804A1 (es) | Quinolinas de alquilnitrilo | |
UY28917A1 (es) | Derivados de tetrahidroisoquinolilsulfonamidas composiciones farmaceuticas y su uso terapeutico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |